StockNews.com assumed coverage on shares of Genocea Biosciences (NASDAQ:GNCA – Free Report) in a research report report published on Friday morning. The brokerage issued a sell rating on the biotechnology company’s stock.
Genocea Biosciences Stock Performance
Shares of GNCA stock opened at $0.00 on Friday. The company has a debt-to-equity ratio of 0.24, a quick ratio of 1.35 and a current ratio of 1.35. The firm has a market cap of $5,873.00, a P/E ratio of 0.00 and a beta of 1.61. Genocea Biosciences has a twelve month low of $0.00 and a twelve month high of $0.00.
About Genocea Biosciences
Further Reading
- Five stocks we like better than Genocea Biosciences
- Find and Profitably Trade Stocks at 52-Week Lows
- Real Estate Sector Outperforms: 3 Stocks to Gain Exposure
- What Are Dividends? Buy the Best Dividend Stocks
- Lam Research Proves Analysts Wrong with a Strong Earnings Report
- Why is the Ex-Dividend Date Significant to Investors?
- PureCycle: Up 250% in 2024 – Is This Materials Stock Still a Buy?
Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.